{"name":"Envista Holdings","slug":"envista","ticker":"NVST","exchange":"NYSE","domain":"envistaco.com","description":"Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including","hq":"Brea, California, USA","founded":0,"employees":"12000","ceo":"Paul Keel","sector":"Dental / MedTech","stockPrice":26.76,"stockChange":1.47,"stockChangePercent":5.81,"marketCap":"$4.4B","metrics":{"revenue":2566500000,"revenueGrowth":15,"grossMargin":55,"rdSpend":114000000,"netIncome":47000000,"cash":1211699968,"dividendYield":0,"peRatio":95.6,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Envista Holdings Reports Fourth Quarter and Full Year 2023 Results","summary":"Envista Holdings reported fourth quarter and full year 2023 results, with revenue of $1.1 billion and adjusted earnings per share of $0.93.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Envista Holdings Acquires Dental Imaging Company","summary":"Envista Holdings acquired a dental imaging company to expand its product portfolio and improve its market position.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQc1BUX2JCUjNTTUU0QllMbzFHRWdpMWtSNExUQXc4RS1nTFBtT0JmUTdIR2xxb1hJcktuQlRUQ0RwbHpmLUVacHdjcEJvNHlHUWZOY1NmT1pZYlVqcFNqS19oSlZpUTVlSVJjU3ZEYV9lc0x0RnpBYVF6QU5Ed19iTjlWZlgwVFRSLTFsb3c1V3FVV3RKZGQ3WXp3V0F5cnRBdE1CeXRoVlRoWHlPbWkwRHBnSzQ2Mkk?oc=5","date":"2026-04-07","type":"pipeline","source":"TradingView","summary":"Reasons to Add Veeva Systems Stock to Your Portfolio for Now - TradingView","headline":"Reasons to Add Veeva Systems Stock to Your Portfolio for Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQOUV0Wmw0M2R5N3dJdWhtSGxxbzZYOV9TQTh4dDlYclh0SUMteThPMkhmdGViQWEzbzdreWVsaWNDcGxJQU9SWDcyRkR2WkZkNGc1dzM2SGkzRU5kS1lRWl9OdFNNa2lDYVVsMG1Rc0E4RlRtNGJjbWFvaDBiY1RPdVJHczlRQjQ5VV9yYU9VbGlYSEQ3RlVoNklTdDFwWGpxcllyN3ZEdGRqbkRvVmplVVBRNW1IYXhDQUE?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Envista (NYSE: NVST) outlines 2026 virtual meeting, proposals and 2025 results - Stock Titan","headline":"Envista (NYSE: NVST) outlines 2026 virtual meeting, proposals and 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNb0NwS2tMemNhMGZ4NURaSWI1ZUR2QnlIc2gwaHBfSjYzanJYVlc2WFJCd3ZvcFNkbFRuX0E2X2hoU1o4V1hfWHZSbXlkZ2M0Y0xwR3MwRE5PQTRaejd2d0hMMy10cU5Qb0dFZzJBOW9fT2kxYzBGLTJSQm1wZ21FSnd1NWF5LW5Ydi1TSHMxTHNUME5HVWxHRmlSUVNOR0lwcF9FeXdpMUlFQVZvZGhKNkZfMVFUR1BnNGJTWUhCQmQ4U241MDg1S0VRQQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"Vanguard disaggregates holdings; reports 0 Envista shares (NVST) - Stock Titan","headline":"Vanguard disaggregates holdings; reports 0 Envista shares (NVST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOSmJ5clN3ei1nVlI4Ym5FRWR1WEV0d190Z2xkZl9UbjlkenpLSzJHMER6NVVSSEZiVzl6YkxicWpfT0RfOC1mTF8yTjFHRmhDQURvX2d2aTlUMTI4LUxrRDRoRjVGZW1zVHhOTWNlRHpsUjJZZ3huNGR2NFJXeTVyZTFvVURGZHQ3NmtRR19RWEZCN2x3SlU4R1dFcDBCRGtka0dMSDBOWUpxNS1oUmFINXFIS0hJUlFZQmc?oc=5","date":"2026-03-18","type":"pipeline","source":"StockStory","summary":"1 Healthcare Stock with Exciting Potential and 2 We Ignore - StockStory","headline":"1 Healthcare Stock with Exciting Potential and 2 We Ignore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbEhNa3JNVC1kaE5MTklJT3BMd2pQSGlLVGNkTFhNamFyRkRsUUVDSVVzN1BFelM0UVpZZkZyTGxzTlVxV09MeGZPM01SV2NUeVJROUl1Y1FkQUlwQVFnQ3BNRVNzVzRKRHJBUHR3aFBnMnhsUWctdEppMlJoYm9iUmR0aWZpeXZldktlUGhUV3dTd1M0aHhWZGhOWk41eW9PaENSR25NMloxY3ctMW04VGNlZE4zR0NZZFhfZXNIc3dVQQ?oc=5","date":"2026-03-06","type":"pipeline","source":"TradingView","summary":"Is This the Right Time to Hold Thermo Fisher Stock in Your Portfolio? - TradingView","headline":"Is This the Right Time to Hold Thermo Fisher Stock in Your Portfolio?","sentiment":"neutral"},{"date":"2026-02-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNNExON3F3Vml1QU1UNWRCTWxYV3RkSGZjZ1BWTk1QUzdXalNaMUNwOUlUX1JpdlRyQWFOR001bVBrQUZkb2thR1dqcmRnWm54emdBRDh3Z2VNdTQ1SEEwRW11N2lYdXRVRmRrNGdfczREUlFMT3lFLXRSb2tVcXlxdjl1emZ5azJlUUdnS2xzZHRrUmtWRVFKVzZJRk1BNWV1Yk9oQ295SVl0dFhQM29mcnJDUUh1Q0pjSktyaVlsRU1EbHlX?oc=5","date":"2026-02-11","type":"pipeline","source":"StockStory","summary":"1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid - StockStory","headline":"1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPMm5YNEUzcUZnY1Q5VFZMUU1HcWd4Vzh0eDU0SnV0eERKQU5TSmNXQ09xVzZ1WFpQQ0NQN0tVS2ZZSTJrZjBEWlNuTVJvSGliR1lHdHB5MjQ1d1hCZ2xQZWFPQk90YmV5UkM2aUh4Rlp2VjNkNElFaGx4akFTSGxJZDNycVo2ZVpRaWJvSlBKZHZfSkxuSXJNRFFudzMxLWxYTHc0c25LOU9QaDhmUEdGSHhhekM?oc=5","date":"2026-02-06","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQS1lZVzRzakhIRFVWRGpHZzNseGdHM3NTVjBnLVVwVThvZEZjem1LQ0JWd3cwZ0Zaa0JWenJxUnY4dHRGaXZCQ1NlTFBqU2JlY0UyQ2dOazVEYnR6RHZvSi1DOWxMcHQ0X1dvcGozOW1ydUZDSml0WUpBOTViMnM2LWlEYjI2R01aZDZRN3NCaGlwdndDVjFwSHJZbkowUVdy?oc=5","date":"2026-02-05","type":"earnings","source":"PR Newswire","summary":"Envista Reports Fourth Quarter 2025 Results - PR Newswire","headline":"Envista Reports Fourth Quarter 2025 Results","sentiment":"neutral"},{"date":"2026-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPMWVXa1hSMDhsZUFLMktYNlRtd3RJcTRDbFA3aXJ1N2lPNE9FcW0tOWUzTTB3cmRwUkNTc3JCMElUTmpSZGx2dkJmT2JJU1g2ZjZIazYta0xSdG9XVGRqb1VXN0NwakpIbjQzbEdRVlljUTVIWWdlNjdVdE02Y2hTRGJXZG1FS2ZIQmJfRU5KWXpFZw?oc=5","date":"2026-01-26","type":"pipeline","source":"Seeking Alpha","summary":"Envista: Anticipating A FY25 Beat (Rating Upgrade) - Seeking Alpha","headline":"Envista: Anticipating A FY25 Beat (Rating Upgrade)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPNXBwcExQRmdGczh0YWNvTGFSNWlldHlSc291UC1SQXpCQWZDT3B0SE5zQzM1cVROOVlfZnh4Ml8yeHJFbzFJN1lHTU9iSEtrUmhJY2N2Z0x0dFVjTENCbDJkY1FSeURmNGF1SXRxeGJpQ3pkdFpHYjZZWHlKc3kwMFl3V0xTd0ZJalBFVlhoMG51SkxfVkJ1eFZyWjYtN0Rnb2NhQW1rdzAtdERRYmFRVTUxWGhacGE0RTk4cU9Bdnpnb28?oc=5","date":"2026-01-07","type":"pipeline","source":"PR Newswire","summary":"Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire","headline":"Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPTkZ5MWJlUlNFWnVfamphcm5WZ0ZoSWdiWmFHYWJMbEN4SmNaemcySkJEUGRUdEhqaEVwWWNwLXZyaGpnMTNsQ2V3UDBiN0dWSXdjM0VlaDVjWHNPVktMc2kzY1NRdE9qNXNvbFdHeWU5UXV0R1BqX0pPX3R5X1VkNE9WTk9SOXMxNHdFZ3Z1R2QzTTU4VkV2MnMxQnl3SE1HcDlwck1XUl9JZXZVNjlURw?oc=5","date":"2025-10-17","type":"pipeline","source":"Seeking Alpha","summary":"Envista: Consider Survey Findings And Peer Disclosures (Rating Downgrade) (NYSE:NVST) - Seeking Alpha","headline":"Envista: Consider Survey Findings And Peer Disclosures (Rating Downgrade) (NYSE:NVST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQdUdoelZJQWFhODJYaWtpNFlKM2Z2NnJwc2xGVU9nWGx6ZjdXUnIyZl9UYU50Rms2MmJHLThKSG1lS1NCM2UydERhamVNSXUyV0ljRDh3NmNUU0hTcmJZVURzemdKZHg2THVDSzBUOGZlSWtJaHd4Q1NqY1BJVXRMSVpSWDQ0WmFKWTFvV1l6OGkwSXU4Y3Y1RzJJV2xkOTB0Wi1QcHlJR2NVY2tjRDNiOVVhTVliSWRuUjQyYzJ2TkJfME8wSVBDYjFzdWpyX25Va2c1THZYcEpxUUpTSXRIRFEybHNySTNwQkxwVkF5VXM4OVVpVnF0Wjcwb2ZTVW50Ums0?oc=5","date":"2025-10-10","type":"pipeline","source":"TradingView","summary":"Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know - TradingView","headline":"Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Dentsply Sirona","Henry Schein","Straumann"],"therapeuticFocus":["Dental Implants","Orthodontics","Dental Imaging"],"financials":{"source":"sec_edgar","revenue":2566500000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":2566500000,"period":"2023-12-31"},{"value":2569100000,"period":"2022-12-31"},{"value":2569100000,"period":"2022-12-31"},{"value":2508900000,"period":"2021-12-31"},{"value":2508900000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":114000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":47000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":5679000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":26.76,"previousClose":25.29,"fiftyTwoWeekHigh":30.42,"fiftyTwoWeekLow":14.22,"fiftyTwoWeekRange":"14.22 - 30.42","fiftyDayAverage":26.55,"twoHundredDayAverage":22.21,"beta":0.98,"enterpriseValue":4530408960,"forwardPE":17.2,"priceToBook":1.41,"priceToSales":1.62,"enterpriseToRevenue":1.67,"enterpriseToEbitda":12.53,"pegRatio":0,"ebitda":361500000,"ebitdaMargin":13.3,"freeCashflow":232762496,"operatingCashflow":275700000,"totalDebt":1597699968,"debtToEquity":51.4,"currentRatio":2.38,"returnOnAssets":2.8,"returnOnEquity":1.6,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":28.67,"targetHighPrice":35,"targetLowPrice":19,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.5,"institutionHeldPercent":113.6,"sharesOutstanding":163875397,"floatShares":163175649,"sharesShort":7296729,"shortRatio":2.84,"shortPercentOfFloat":4.4,"epsTrailing":0.28,"epsForward":1.56,"revenuePerShare":16.19,"bookValue":18.96,"officers":[{"age":55,"name":"Mr. Paul A. Keel","title":"CEO & Director"},{"age":50,"name":"Mr. Eric D. Hammes","title":"Senior VP & CFO"},{"age":57,"name":"Mr. Mark E. Nance J.D.","title":"Senior VP, General Counsel & Secretary"},{"age":53,"name":"Mr. Mischa M. Reis","title":"Senior Vice President of Strategy & Corporate Development"},{"age":51,"name":"Mr. Robert  Befidi Jr.","title":"President of Diagnostics"},{"age":56,"name":"Mr. Faez  Kaabi","title":"VP, Chief Accounting Officer & Corporate Controller"},{"age":null,"name":"Mr. Andrew  Chen","title":"Chief Information Officer"},{"age":null,"name":"Mr. Jim  Gustafson","title":"Vice President of Investor Relations"}],"industry":"Medical Instruments & Supplies","irWebsite":"","website":"https://envistaco.com","phone":"714 817 7000"}}